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Abstract
Background: Combinatorial RNA interference (co-RNAi) approaches are needed to account for viral variability in
treating HIV-1 with RNAi, as single short hairpin RNAs (shRNA) are rapidly rendered ineffective by resistant strains.
Current work suggests that 4 simultaneously expressed shRNAs may prevent the emergence of resistant strains.
Results: In this study we assembled combinations of highly-conserved shRNAs to target as many HIV-1 strains as
possible. We analyzed intersecting conservations of 10 shRNAs to find combinations with 4+ matching the
maximum number of strains using 1220+ HIV-1 sequences from the Los Alamos National Laboratory (LANL). We
built 26 combinations of 2 to 7 shRNAs with up to 87% coverage for all known strains and 100% coverage of clade
B subtypes, and characterized their intrinsic suppressive activities in transient expression assays. We found that all
combinations had high combined suppressive activities, though there were also large changes in the individual
activities of the component shRNAs in our multiple expression cassette configurations.
Conclusion: By considering the intersecting conservations of shRNA combinations we have shown that it is
possible to assemble combinations of 6 and 7 highly active, highly conserved shRNAs such that there is always at
least 4 shRNAs within each combination covering all currently known variants of entire HIV-1 subtypes. By
extension, it may be possible to combine several combinations for complete global coverage of HIV-1 variants.
Introduction
HIV is characterized by high sequence variability with
many hundreds of genetically unique strains [1,2]. These
are classified based on changes in the viral envelope
with 3 groups (M, N, and O) and several subtypes (or
clades). There is a geographical clustering for each, with
group M the main grouping globally and clade B
the most common subtype in USA and Europe [2]. The
only effective way to currently treat HIV is with the
simultaneous use of multiple antiretroviral drugs to pre-
vent the emergence of drug-resistant strains [3]. RNA
interference (RNAi) is a recently discovered mechanism
of gene suppression that has received considerable
attention for its potential use in gene therapy strategies
for HIV (for review see [4-6]). Expressed short hairpin
RNA (shRNA) effectors are well suited for potential use
in gene therapy. Sharing structural similarities to natural
microRNA, shRNA consists of a short single stranded
RNA transcript that folds into a ‘hairpin’ configuration
by virtue of self-complementary regions separated by a
short ‘loop’ sequence. shRNA is commonly expressed
from U6 and H1 pol III promoters. These promoters
are compact, active in many tissues, and are well suited
to shRNA expression due to their relatively well-defined
transcription start and end points. Importantly, pol III
based shRNA expression cassettes have been incorpo-
rated into viral vectors which have been stably inte-
grated both in culture and whole animals with effective
silencing maintained over time [7-9].
The potency of individual shRNA has been extensively
demonstrated in culture and there are now several hun-
dred identified targets and verified shRNAs for HIV
[10-12]. However, single shRNAs can be rapidly over-
come by viral escape mutants possessing small sequence
changes that alter the structure or sequence of the tar-
geted region [13-16]. A combinatorial RNAi approach
using multiple shRNAs is required to prevent the emer-
gence of resistant strains [17-19], with models predicting
that as few as 4 shRNAs will be sufficient [19,20]. How-
ever, this requires all 4 shRNAs to be matched to each
of the 100’s of circulating viral variants spanning the
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have shown much promise in laboratory tests, though a
number are of limited clinical relevance in terms of tar-
get sequences [11,16,21-23]. This is because they tend
to be assembled on the basis of the individual conserva-
tions of the component shRNAs without consideration
of the intersecting conservation of the entire combina-
tion, where the highest individual conservations are not
necessarily reflected in the intersecting conservation.
This is an important point, as some strains will be
(inadequately) covered by fewer than the intended num-
ber of shRNAs, thus facilitating the emergence of escape
mutants. Unless all 4 shRNAs are effectively conserved
across all targeted strains (unlikely), then more than 4
shRNAs will be required to attain at least 4m a t c h e dt o
each different strain (Figure 1).
There are a number of potential methods for co-
expressing multiple shRNA, including: multiple expres-
sion vectors [9,24,25], multiple expression cassettes from
as i n g l ev e c t o r[ 1 1 , 2 6 , 2 7 ] ,a n dl o n gs i n g l et r a n s c r i p t s
composed of an array of multiple shRNA domains
[16,21,28-30]. The latter strategy is advantageous for
gene therapy as it uses the fewest promoters, is the
most compact and can be designed to mimic natural
polycistronic miRNA clusters [22,30-32]. However, it is
also the most difficult to currently use with many design
variations and no clear guidelines. We and others have
found that the original suppressive activities of the com-
ponent shRNAs were not necessarily maintained in
combination, and combinations of more than 2 shRNAs
became increasingly difficult to assemble [16,28,29,33].
Moreover, effective combinations may be limited to only
3 domains, which is too few [34]. The multiple cassette
strategy is a most useful method for immediate use due
to its ease of design, assembly, and direct compatibility
with pre-existing active shRNA. Others have also used
this co-expression strategy to investigate multiple
shRNA treatments for viral diseases, using cassette com-
binations ranging from 2 to 6 [11,26,27,35,36].
The primary aim of this study was to mathematically
assemble and select combinations of highly-conserved
anti-HIV shRNAs to target a maximum number of viral
variants whilst minimizing the risk of selecting for
escape mutants. We also aimed to characterize the
intrinsic individual and combined suppressive activi-
ties of the component shRNAs when simultaneously
expressed. We made 26 combinations of 2 to 7 shRNA
with some containing at least 4 shRNA fully matched to
100% of clade B sequences, and up to 87% of all other
clades. We found that while all combinations had high
combined suppressive activities, the individual activities
of the component shRNAs could vary compared to the
corresponding single shRNAs. Importantly, we present a
method by which highly relevant combinations can be
selected, and have shown that a surprisingly small num-
ber of shRNAs can combined into single combinations
with the potential for targeting entire subtype groups.
Results
A selection of anti-HIV shRNA
We have previously analyzed over 8000 unique 19
nucleotide (nt.) HIV-1 targets, and calculated their level
of conservation amongst almost 38000 HIV gene
sequence fragments containing 24.8 million 19 mers
[12]. We characterized 96 in detail, and 10 of these,
spanning 7 genes, were selected for assembly into com-
binations here (#0 - 9) (Table 1). This selection was
based on a combination of activity, conservation and
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Figure 1 More than 4 shRNAs are needed to obtain 4 matched to all variants. Models predict that a minimum of 4 shRNAs is needed to
prevent the emergence of viral escape mutants, however, this requires 4 shRNAs to be matched to all viral variants spanning the different
subtypes. Unless all 4 shRNAs are 100% conserved across all targeted strains (unlikely) (A), then more than 4 shRNAs will be required to attain at
least 4 matched to each different strain (B). By studying the intersecting conservations of combinations as a whole, combinations can be
assembled such at at least 4 shRNAs (4+) for a given combination (of > 4 shRNAs) are matched to all relevant strains.
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Page 2 of 15target diversity, with a bias towards selecting highly con-
served sequences. The selected shRNAs were either
active (> 50% activity) or highly active (> 75% activity),
and the average conservation for the central cores (the
first 19 nt. of each stem) was 74% amongst all known
sequences and 85% for clade B subtypes. Our estimates
of conservation were as stringent as possible in that we
only regarded shRNAs that were fully matched as con-
served (i.e. no mismatch tolerance). It may well be that
our shRNAs are active against an even greater number
of variants than we predict as some shRNAs can retain
partial or full activity with some degree of mismatch to
their targets. It is interesting to note that the two LTR
shRNAs (#0 and 1) we chose were 100% conserved in
clade B subtypes. It is also interesting that whilst our
selection process was entirely independent of prior stu-
dies, several of our selected shRNA target sites (e.g. #3,
4 and 7) are highly similar to those identified by others;
see our earlier report for a relevant list [11,12,37].
Transferring shRNAs and confirming target-specificity
Our 10 shRNAs were first transferred from pSilencer
type plasmids [12] as complete expression cassettes (H1
promoter, shRNA region and terminator) into our Len-
tivirus transfer plasmid setup with an infinitely expand-
able MCS [38]. This setup enables any number of PCR/
sub-cloned cassettes to be sequentially inserted by using
restriction enzymes (REs) that are repeatedly destroyed
and simultaneously re-introduced with each round
of cloning (Figure 2). The transferred shRNA were
each assayed for suppressive activity using 9 different
fluorescent reporters matched to each shRNA (n.b. the
two overlapping LTR shRNAs, #0 and #1, shared the
same reporter) (Figure 3a). This was to confirm the spe-
cificity of each shRNA to enable us to accurately test
the individual activities ofs i m u l t a n e o u s l ye x p r e s s e d
shRNAs without reporter cross-reactivity. Each shRNA
expression plasmid was co-transfected into HEK293a
cells with two reporters; the corresponding target-speci-
fic GFP fusion and a non-specific AsRed-1 fusion. Tar-
get-specific fluorescence was measured 48 hours later,
normalized to the fluorescence of the non-specific
reporter, and activities were calculated relative to the
fluorescence levels of a control plasmid with an empty
expression cassette (composed of the H1 promoter, but
no shRNA). All transferred shRNA maintained a com-
parable level of target-specific activity to that measured
previously from the original plasmids, without reporter
cross-reactivity (except that expected for #0 and #1)
(Figure 4).
Selecting combinations to maximize intersecting
conservation
We mathematically assembled the 10 chosen shRNAs
into all possible combinations of 4, 5, 6 and 7 different
shRNAs with disregard to order. The total number of
combinations (k) from a given set size (n) can be found
by the combinatorial ‘choose function’: n!/(k!(n - k)!).
For example, 10!/(4!(10-4)!) equalled 210 possible com-
binations of 4 shRNAs from our selected set of 10.
Table 1 The 10 shRNAs
#
a Target -2 -1
b 19 nt. core + 1/2 nt.
c Loop
d T.
e B
f ALL
g
0 LTR 510-21 AA CCCACTGCTTAAGCCTCAATA ACTCGAGA 100 70
1 LTR 527-21 TC AATAAAGCTTGCCTTGAGTGC ACTCGAGA G 100 93
2 Gag 533-20 AG GAGCCACCCCACAAGATTTAT CTCGAGT8 0 70
3 Pol 248-20 AG GAGCAGATGATACAGTATTAC CTCGAGC8 7 8 0
4 Pol 2670-21 GC AGTACAAATGGCAGTATTCAT ACTCGAGA G7 47 3
5 Pol 2878-20 AA GGTGAAGGGGCAGTAGTAATT CTCGAGT8 0 74
6 Vif 9-21 AA CAGATGGCAGGTGATGATTGT ACTCGAGA9 2 71
7 Tat (x1) 140-21 CT ATGGCAGGAAGAAGCGGAGAC ACTCGAGA A7 77 3
8 Vpu 143-20 AA GAGCAGAAGACAGTGGCAATC CTCGAGC8 3 66
9 Env 1428-21 AA TTGGAGAAGTGAATTATATAA ACTCGAGA8 1 73
a shRNA reference number (#) used in this study.
b The two nt. immediately upstream of the 19 bp core target site were taken into consideration when estimating individual shRNA conservations but not included
in the shRNA stem, nor used in calculating intersecting conservations.
c The shRNAs had 20 or 21 bp stems built around a 19 bp core placed at the base terminus of the shRNA which was extended by 1 or 2 nt. with target matched
sequence at the loop terminus, as indicated in bold (and used when estimating individual shRNA conservations).
d If the core was made into a 20 bp hairpin stem, then the last nucleotide of the loop was selected to be the complement of the last nucleotide of the p+2
position so that if the processed siRNA product(s) included the the last nucleotide of the loop then it too would be matched to the target (indicated by
underline).
e The shRNAs in which the last base of the anti-sense stem was ‘T’ also included a ‘termination spacer’ so as to prevent premature termination via an early run of
‘T’s. This nucleotide was always the complement of the first nucleotide of the p-1 position (but never a ‘T’), so that if included in the processed siRNA product(s)
it was also matched to the target.
f % conservation for the 19 bp core in LANL clade B sequences only.
g % conservation for the 19 bp core in ALL LANL sequences, irrespective of clade.
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Page 3 of 15There were 252 possible combinations of 5 shRNAs, 210
of 6, and 120 of 7. For each combination we calculated
the intersecting conservations, from at least 4 of the
component shRNAs, using the first 19 bp of each
shRNA stem in accord with our previous target conser-
vation profiling method [12]. Intersecting conservations
were calculated using 1224 HIV-1 genome sequences,
some with incomplete LTR sequence, obtained from the
Los Alamos National Laboratory in 2007 (LANL; http://
www.hiv.lanl.gov). We created 4 sub sets from these: all
clade B sequences (229 sequences), all other clades
(995), clade B sequences that contained sufficient
LTR sequence to analyze combinations including
our LTR shRNAs (127), and all other clades with suffi-
cient LTR sequence (549).
There was generally poor intersecting conservations
from combinations of 4 shRNAs. Several combinations of
5 had at least 4 shRNAs (4+) conserved in 89 - 97% of
clade B sequences, though only 40 - 58% in all other sub-
types (Table 2). But some combinations of 6 and 7
shRNAs had 4+ intersecting conservations of 98 - 100%
in clade B and 65 - 87% in all other subtypes. We selected
17 combinations to construct, composed of 6 combina-
tions of 5× shRNAs, 8 combinations of 6× shRNAs, and
3 combinations of 7× shRNAs. Our selection included
combinations that excluded LTR shRNAs as there is still
some uncertainty surrounding the accessibility of the
incoming virus and the LTR as an in-vivo RNAi target
[39-41]. Though given the possibility [37,39,40], we also
selected combinations that specifically included LTR
shRNAs as they had the highest individual conservation
levels. Combinations including overlapping shRNA
targets (e.g. shRNAs #0 and #1) were discounted.
The shRNA order of each combination was chosen to
minimize construction steps by creating common sub-
combinations from the most common shRNAs first. In
total, there were 26 combinations assembled including
9 sub-combinations of 4 or less shRNAs required for our
17 final combinations of 5 to 7 shRNAs.
Establishing positional differences in combinations of up
to 7 cassettes
We also created 33 controls, composed of 6 empty cas-
sette combinations of 2 - 7, and 27 combinations of a
single shRNA (shRNA #3; Pol 248-20) surrounded by
1 or more empty expression cassettes (in combinations
of 2 - 7). In this way our control shRNA could be tested
in each position for potential effects by neighboring pro-
moters without competition from other shRNAs for
the RNAi machinery. The suppressive activity of the 27
plasmids was tested using the fluorescent reporter assay
with the corresponding reporter (Pol-1), across a titrated
range of shRNA plasmid amounts from 400 ng to 1 ng
(Figure 5). There was a trend towards decreased activity
from plasmids with increased cassette number, irrespec-
tive of cassette position, which was most apparent for
the 6 and 7 cassette plasmids at low doses. Suitable
activity was, however, maintained in all variants for the
high to mid doses tested (400 - 100 ng), with respective
standard deviations in apparent suppressive activity of
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Figure 2 An infinitely expandable cloning strategy. In the example of our multiple cassette cloning strategy shown, a 7th cassette is being
inserted into a vector that already has 6 cassettes integrated (A). The incoming donor fragment is a PCR amplified shRNA expression cassette
(B) digested with ‘a’ (Mlu I) and ‘b’ (Asi SI) restriction enzymes (REs) which is ligated to the recipient vector opened up with ‘A’ (Asc I) and ‘B’ (Pac
I) REs destroying the original ‘a’, ‘A’,b ’, and ‘B’ sites in the process. The newly created vector has the ‘A’ and ‘B’ sites reconstituted via the
incoming donor fragment, ready for insertion of subsequent cassettes. Each shRNA expression cassette included the H1 promoter, shRNA,
terminator and some flanking sequence to a total length of ~ 270 - 300 bp. (C) All 10 single shRNA expression cassettes were first transferred
from pSilencer type plasmids (as assembled in prior work) as complete expression cassettes into single shRNA Lentivirus transfer plasmids (setup
with an infinitely expandable MCS as detailed above).
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Page 4 of 152% and 5% across all positions in all combinations. This
confirmed that cassette order had no obvious effect on
intrinsic suppressive activity.
Individual activities measured under simultaneous
expression
We measured the individual suppressive activity of each
shRNA within all combinations when expressed simulta-
neously using our fluorescent reporter assay. Every com-
bination and the 10 single shRNA plasmids were
separately transfected with each matched reporter
(Figure 6). Thus, the apparent suppressive activities
likely reflect the individual suppressive contribution of
each shRNA to the total. The activities from the single
plasmids matched those seen previously. Likewise, the
activity of shRNA #3 (the first position in all combina-
tions) was similar for all combinations and the single
shRNA plasmid. Activities from the second position
shRNAs were also comparable to the single shRNA plas-
mids, however, all shRNA activities from position
3 onwards were notably reduced relative to the single
shRNA plasmids. This was most obvious for shRNA
#9 in positions 3, 4 and 5, and #1 in position 5; irrespec-
tive of total cassette number. Activities from each
shRNA generally clustered, regardless of the position or
length of the combination it was present in. For exam-
ple, while the activities of combinations of 3 to
7 shRNAs measured for shRNA #7 in positions 3, 5 and
6 (i.e. measured with reporter Tat ×12) differed on aver-
age more than 2 fold from the #7 single shRNA, they
had a standard deviation of only 4.8%. Our data suggests
that shRNA competition may reduce the individual sup-
pressive activities of simultaneously expressed shRNAs,
with some sequences more susceptible than others.
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Figure 3 Reporter maps.( A) Each reporter contained GFP fused upstream to one of the accessory genes (for shRNAs #0, #1, #6, #7, and #8), a
fragment of the core genes (#2, #3, and #9) or a small shRNA-specific target domain (#4 and #5) with stop codons placed between the two
domains. Thus, each reporter produced a fused mRNA target composed of GFP plus the HIV-1 sequence from which only the GFP domain was
translated. This was engineered to remove the possibility of HIV-1 protein products affecting shRNA activity. (B) We made an all-in-one reporter
(the aio sense reporter) to measure the combined activity of simultaneously expressed shRNAs. It had a ~ 400 bp target domain composed of 8
sections of ~ 40 bp covering each ~ 20 bp shRNA target site plus ~ 10 bp either side, and one slightly longer shared section for the two LTR
targets since they overlapped each other. Two more reporters were also made (though not shown schematically): the reverse complement of
the aio sense reporter (the aio anti-sense) and a non-matched control reporter composed of 7 similarly sized target domains that were
unmatched to the chosen shRNAs.
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Figure 4 shRNA specificity and activity was maintained in transferred expression cassettes. Each shRNA expression plasmid was
co-transfected into HEK293a cells with two reporters; the corresponding target-specific GFP fusion and a non-specific AsRed-1 fusion. All shRNA
were separately tested with the 9 reporters individually matched to each shRNA (n.b. two LTR shRNA, #0 and #1, shared targeted the same
reporter). Target-specific fluorescence levels were normalized to non-specific effects measured with the AsRed-1 fusion, and presented relative to
the fluorescence levels from the corresponding empty expression cassette plasmid (value set at 100%; not shown). A key to the reference #s
used in the original study is given below the 0 - 9 #s used here for cross-reference. Off-scale values (> 100%, i.e. no activity) are indicated by
open circles without error bars, and with text labels where appropriate. Error bars are 95% Confidence Intervals (CI) from 3 independently
repeated experiments.
Table 2 Percentage conservations for the combinations
229 sequences 995 sequences 127 sequences 549 sequences
Clade B
d Others
e Clade B (LTR)
f Others (LTR)
g
#
a Combin.
c 4+ 5+ 6+ 7+ 4+ 5+ 6+ 7+ 4+ 5+ 6+ 7+ 4+ 5+ 6+ 7+
5.1 3.4.7.2.9 89 48 - - 54 15 - - 91 53 - - 58 15 - -
5.2
b 3.4.7.2.0 n/a n/a - - n/a n/a - - 94 57 - - 57 23 - -
5.3 3.8.9.2.7 92 49 - - 40 13 - - 94 54 - - 41 15 - -
5.4
b 3.8.5.9.0 n/a n/a - - n/a n/a - - 95 64 - - 58 20 - -
5.5 3.8.5.2.9 92 53 - - 48 12 - - 94 59 - - 54 13 - -
5.6
b 3.8.5.2.1 n/a n/a - - n/a n/a - - 97 65 - - 53 10 - -
6.2
b 3.4.7.2.0.5 n/a n/a n/a - n/a n/a n/a - 100 89 51 - 81 50 15 -
6.3 3.8.9.2.7.6 100 86 46 - 65 26 4 - 99 89 49 - 67 23 3 -
6.4
b 3.8.5.9.0.6 n/a n/a n/a - n/a n/a n/a - 100 88 60 - 75 38 5 -
6.5
b 3.8.5.2.9.0 n/a n/a n/a - n/a n/a n/a - 99 94 58 - 80 45 13 -
6.6 3.8.5.2.9.7 99 87 43 - 68 31 9 - 98 92 4 7 - 7 33 41 0 -
6.7
b 3.8.5.2.1.7 n/a n/a n/a - n/a n/a n/a - 100 94 53 - 75 30 7 -
6.8
b 3.4.7.2.0.6 n/a n/a n/a - n/a n/a n/a - 99 88 52 - 77 40 5 -
6.9 3.4.7.2.9.5 98 84 43 - 75 45 9 - 98 87 4 7 - 7 95 01 0 -
7.3
b 3.8.9.2.7.6.0 n/a n/a n/a n/a n/a n/a n/a n/a 100 98 89 48 87 57 22 3
7.5 3.8.5.2.9.7.6 100 99 81 41 84 56 18 3 100 98 84 44 85 58 17 2
7.7 3.4.7.2.9.5.6 100 96 80 40 86 64 31 3 100 94 83 43 86 64 34 2
a Combination reference number (#) used in this study.
b As these combinations contained an LTR shRNA (0 or 1) the intersecting conservations calculated on all sequences (where a large number lacked LTR sequence
coverage), were not applicable (n/a); only the LTR containing subset were used, as shown.
c The component shRNAs (in order of arrangement) for each combination.
d The clade B sequences only.
e The sequences of all other clades (excluding clade B).
f The subset of clade B sequences that contain LTR sequence coverage.
g The subset of all other sequences (non B) that contain LTR sequence coverage.
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We made a new all-in-one reporter (the aio sense
reporter) to measure the combined or total activity of
all shRNAs within each combination acting in concert
against a single target transcript. This reporter had a ~
400 bp target domain composed of fused target sections
for our 10 chosen shRNAs (Figure 3b). There were 8
sections of ~ 40 bp covering each ~ 20 bp target site
plus ~ 10 bp either side, and one slightly longer shared
section for the two overlapping LTR targets. Two addi-
tional reporters were also made. One was the reverse
complement of the aio sense reporter (the aio anti-
sense) designed to measure suppressive activity of the
siRNA passenger strand derived from the anti-sense
shRNA stem. The other was a non-matched control
reporter composed of 7 similarly sized target domains
that were unmatched to the chosen shRNAs. To go with
this last reporter, we assembled a series of 7 corre-
sponding non-matched single shRNA controls and used
them to make 2, 3, 4, 5, 6 and 7 cassette control combi-
n a t i o n s .T h es e q u e n c e so ft h es i n g l es h R N Ac o n t r o l s
were derived from the backwards sequence of shRNAs
#3, #8, #9, #2, #7, #6 and #0. In this way they were
unmatched to the aio reporters yet had identical nucleo-
tide compositions (but in reverse order) to retain similar
thermodynamic profiles.
Combined activities measured with an all-in-one reporter
All single shRNA, combinations, and non-matched con-
trol plasmids were separately transfected with all three
reporters (Figure 7a) (Additional file 1 for the control
data). The aio sense reporter activities for the 10 single
shRNA differed slightly in magnitude to that seen with
the previous reporters, but still followed the same rela-
tive pattern. shRNAs #0, #1 and #2 were the least active.
Interestingly, the aio anti-sense reporter showed that
shRNAs #1, #7 (especially) and #8 were being at least
partly processed so that the passenger strand was being
loaded into RISC. The activity of shRNA #1 was particu-
larly poor, with the passenger strand exhibiting greater
suppressive activity than the guide strand. The activities
for all combinations of 2 through to 7 cassettes were
similar to each other and the activities of the most
active single shRNA (measured with the aio sense repor-
ter). It may be that this was close to the highest silen-
cing level achievable with the aio reporter under the
current conditions of our assay system. There was no
notable passenger strand activity from any combination.
In all cases the single shRNAs and combinations exhib-
ited no notable non-specific effects on the control
reporter. The backwards control shRNAs showed the
expected reverse trend, with no effect on either aio
reporter, but some suppression of the corresponding
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Figure 5 Cassette number and position effects on suppressive activity. Twenty seven control plasmids, each containing a single shRNA
expression cassette (shRNA #3) plus 1 or more empty expression cassettes for all possible 2, 3, 4, 5, 6 and 7 cassette plasmids were tested with
the fluorescent reporter assay using the matched Pol-1 (1 - 436) reporter across a titrated range of shRNA plasmid amounts from 400 ng to
1 ng. The activity of each combination was calculated as a% of the fluorescence from the corresponding control of same cassette number and
~ length but composed entirely of empty expression cassettes (values set at 100%; not shown). Off-scale values are indicated by open circles.
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Page 7 of 15control reporter. Activity levels were spread across the
inactive to active classification groups as the backwards
control shRNAs were neither designed nor previously
selected for activity. Interestingly, the combined
suppressive activities of these mediocre shRNAs at max-
imum dosage was not additive, i.e. resulting in greater
total suppressive activity. Again, no control combination
exceeded the activity of the most active single shRNA.
Titrations to look at sub-saturating differences between
combinations
We repeated the transfections of the aio sense reporter
with each combination, but titrated the amount of single
shRNA or combination plasmid from 400 ng to 1 ng to
determine if there was a sub-saturating point at which
larger combinations were more active than smaller ones
(Figure 7b). The suppressive activities at the higher
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Figure 6 Individual activities measured under simultaneous expression.( A) Every combination and the 10 single shRNA plasmids were
separately transfected with each matched fluorescent reporter corresponding to its component shRNAs to measure the individual suppressive
activities of each shRNA when expressed simultaneously with others. Activities are plotted according to total cassette number and each cassette
position (1 to 7) (B). Different combinations of identical cassette number are grouped in columns (e.g. the 6 combinations of 5 cassettes), shRNA
# is indicated by color coding, and the combination number for individual points is indicated where points differed from the main cluster. The
combination numbers present in each column are given, and also color coded to match the shRNA in the position being tested and the
matched reporter used (C). For example, combinations 6.2 (3.4.7.2.0.5), 6.8 (3.4.7.2.0.6) and 6.9 (3.4.7.2.9.5) in position 2 were assayed with the
Pol-2670 reporter (matched to shRNA #4), and combinations 6.3 (3.8.9.2.7.6) - 6.7 (3.8.5.2.1.7) were assayed with the Vpu reporter (matched to
shRNA #8). Values shown are representative of 3 independently repeated experiments.
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Page 8 of 15dosages were similar to that seen previously, and all
combinations were more active than any of the single
shRNAs at all titration points. This showed that one or
more shRNAs in combinations can exhibit an increased
combined suppressive effect at sub-saturating expression
levels compared to any one of the component single
shRNAs. However, there were no obvious differences
between combinations of different number, with an
average standard deviation of only 2% at all titration
points.
We also measured the titrated activities using shRNA-
specific reporters and a series of related combinations
(2.2, 4.2 and 6.3) and their corresponding single shRNA
plasmids (#3, #8, #9, #2, #7, and #6) (Figure 8). The
activities of the selected single shRNAs at maximum
dosage was generally higher with the shRNA-specific
reporters (cf. the aio reporter), excepting #2, and clus-
tered closely for both reporter types. The individual sup-
pressive activities of each shRNA expressed
simultaneously with all others was reduced relative to
activities from the corresponding single shRNA plasmids
at all titration points, with the exception of shRNA #3
(position 1). shRNAs #9 and #2 in the central positions
(3 and 4) displayed notably impaired contributing activ-
ities when expressed in combination. The positional
overlay connecting the maximum dosages showed the
same pattern as seen previously when testing all combi-
nations. Likewise, the combined activities for all combi-
nations were similar at all titration points, but generally
greater than the component single shRNAs at lower
dosages.
Discussion
In this study we aimed to mathematically assemble,
select and test combinations of highly-conserved anti-
HIV shRNAs to find those with the highest intersecting
conservations of 4+ shRNAs across all known viral
strains. Importantly, we have shown that it is possible,
with careful consideration of the individual and inter-
secting conservations of combinations of shRNAs, to








	










































	









	


	


	


	

	













	


















%



%
$
)
'
%
"



	









	










































	









	


	


	


	

	













	


















%



%
$
)
'
%
"



	














	
$
!%(

!%
&%')'
!$"( $%#!$)!%$()!)')#%*$)($,!) ) ""!$%$($('&%')'
!$"( %#!$)!%$($%$)'%"(,!) ""!$%$'&%')'+'!$)(








	










































	









	


	


	


	

	













	













	








%
(
!
)
!
%
$

/
/








	

-
-
-

-
-
-
	-
	


	







	






	




	



	
.......
..
. ....
...
..
.
.........

! 
&%(!)!%$ 
(())( #)!(
.
Figure 7 Combined activities measured with an all-in-one reporter.( A) All 10 single shRNA plasmids, all 26 combination plasmids, and the
extra non-matched shRNA plasmids (singles plus control combinations (c.c.) - see Additional file 1 for control data) were separately transfected
with the three all-in-one reporters; the aio sense (to measure specific activity of the intended guide strand), the aio anti-sense (to measure
unintended activities from the expected passenger strand), and the non-matched control to measure potential non-specific effects from our
combinations. Off-scale values (> 100%, i.e. no activity) are indicated by open circles and text labels where appropriate. (B) All single shRNA and
combination plasmids were re-tested with the aio sense reporter using a titrated amount of shRNA or combination plasmid from 400 ng to 1
ng. In this example, the filler plasmid used to maintain a constant amount of DNA per transfection was our base lentivirus (backbone) plasmid,
without any cassettes (i.e. competing H1 promoters). Values shown are representative of 2 or more independently repeated experiments.
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Page 9 of 15assemble shRNA combinations against entire subtypes.
Even when selecting the most conserved individual
shRNAs we were unable to identify a combination of 4
that was fully matched to all variants analyzed, as there
were not 4 non-overlapping shRNAs that were 100%
conserved. But with selected combinations of 7 shRNAs
we could attain at least 4 shRNAs matched to 100% of
clade B subtypes, and up to 87% of all other clades - a
highly significant finding. In demonstration of the need
to consider intersecting conservations, 5 of our highest
individually conserved shRNAs (#0|1, 3, 6, 8, and 9) had
an intersecting conservation for clade B subtypes that
was 6% lower than other possible combinations (91 vs.
97%). Also, we found that different combinations were
better suited to different subtypes. For example, the
combinations of 5 shRNAs with the highest intersecting
conservations for clade B subtypes (96 - 97%) had con-
servations for all other subtypes that were between at
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Figure 8 Titrations of a select series of related combinations with individual reporters. We measured the titrated activities for a single
series of related combinations (2.2, 4.2 and 6.3) and their corresponding single shRNA plasmids (#3, #8, #9, #2, #7, and #6) using shRNA-specific
reporters. We overlaid connection lines between the maximum dose values for each shRNA/reporter to show the positional relationship of each
shRNA in the combinations for comparison to the equivalent measurements using the aio reporters. We expanded the titration points for the
same series of plasmids tested with the aio sense reporter, and included them on the same scale for comparison. n.b. we were unable to test
titrated amounts of shRNA #2 with the Gag-500 reporter due to stock contamination. Values shown incorporate representative data from 2
independent experiments.
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Page 10 of 15least 16 and 28% less (34 - 53%) than others most highly
conserved for all other subtypes (62 - 69%). Thus, sub-
type-specific intersecting conservations should also be
considered if tailoring combinations to localities with a
subtype bias.
The data from our series of combinations containing a
single copy shRNA #3 surrounded by empty expression
cassettes revealed that although there was some reduc-
tion in activity for combinations of 6 and 7 shRNAs,
there was no obvious difference in the activities of the
different cassette positions for any combination length.
When we assembled combinations of multiple shRNAs
and tested the individual activities of the component
shRNAs, we found that the shRNAs in positions 1 and
2 were the most active (#3, 4 and 8), and similar in
activity to the corresponding single shRNAs for all com-
binations. However, shRNAs in positions 3 to 7 exhib-
ited a marked reduction in activity compared to their
single shRNA counterparts, irrespective of combination
length or composition, and notably to similar levels for
each shRNA. Some of the corresponding single shRNAs
were highly active (#5, 6, 7 and 9), and just as active as
the single shRNAs corresponding to positions 1 and 2.
We conclude that the shRNAs located in positions 3 to
7 were likely more susceptible to a reduction in suppres-
sive activity due to competition than the shRNAs in
positions 1 and 2. If so, the effect of competition on
individual suppressive activities may, at least in part, be
sequence dependent. Future screens for component
shRNAs for assembly in combinations may benefit from
the inclusion of an additional test to measure individual
suppressive activity when expressed in combination.
However, it is also possible that there may be some
additional positional influence contributing to our
observations from the shRNA combinations that was
not apparent from our shRNA #3 control series. This
possibility could be examined with further work includ-
ing the assembly of permutations of the combinations to
place each shRNA in several different positions whilst
being surrounded by other shRNAs.
Potential competition for the available RNAi machin-
ery between simultaneously expressed shRNAs (and
host cell miRNAs) also needs to be considered. It is
likely that expression level will need to be carefully con-
trolled to maximize the specific activities of the anti-
HIV shRNAs, yet minimize the impact on the natural
miRNA processes. Another potential issue is that the
shRNAs not matched to the given strain may reduce the
individual impacts of those that are matched [16,29],
which implies that combination size should be kept to a
minimum. We also noted from our positional testing
experiments that combinations of > 5 shRNAs began to
show reduced activity from all cassette positions due to
increased size alone. It may be a more effective gene
therapy strategy to use several smaller combinations of
~ 5 shRNAs selected with intersecting conservations
specific to the strains that predominate geographical
locations, rather than a single larger combination to
cover all variants simultaneously.
Although multiple repeated expression cassettes is
currently a most useful co-expression strategy for multi-
ple shRNAs, it has some shortcomings, including con-
cerns regarding long-term stability and efficacy [28]. We
chose this system here not because we necessarily think
that it will be the best in the long run, but because at
the time of design it was the most advanced method
compatible with out goals. We and others have found
that large increases in vector size may affect vector pro-
duction [23,33,42]. It is possible that the impact of these
issues could be reduced or eliminated with fewer cas-
settes, further supporting the use of the smallest effec-
tive combination size. Current designs like ours that use
unregulated pol III promoters may also have to be rede-
signed with regulated or inducible expression units for
in vivo applications (e.g. [22]). Our choice of the H1
promoter (compared to say, the U6 promoter) was
because of our extensive experience with this promoter
and its common use for expressing shRNAs. Further-
more, there are reports that U6 expressed shRNAs may
cause an adverse response in vivo, though this was over-
come by using different pol II promoter types [43].
Other co-expression methods may be ultimately better
suited for our gene therapy, such as single transcripts
composed of multiple target domains. Several such
designs have been tested by others, though in some
cases it has been difficult to attain activity from more
than 3 domains [34,44]. Also, their use will also likely
be complicated by the probability that each domain is
processed in a different manner to the component
shRNAs. As with all co-expression methods, one should
remain mindful of the possibility of unexpected off-
target effects. Additionally, all uses of a lentivirus deliv-
ery system for a HIV sequence-specific treatment such
as shRNA should, at some stage, consider the possibility
that the shRNA used may interfere with the production
of the lentivirus itself. We, however have not yet found
this problematic [45] and the extent to which this would
be a practical problem on a commercial-scale is as yet
undetermined, though there are several ways in which it
may be overcome.
We have since begun testing our combinations in HIV
replication assays and discovered that repeat-mediated
deletion can result in the loss of one or more complete
expression cassettes [45]. We have extensively charac-
terised the frequency of this phenomenon, and modeled
its likely impact on treatment success. Surprisingly, we
have found that even significant amounts of deletion are
unlikely to affect the treatment outcome. Thus, the next
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suppress the emergence of escape mutants over time,
similar to other studies [11,16]. This is the critical
assessment of activity to confirm the theoretical advan-
tages of multiple shRNAs frequently speculated upon
[46-48], and supported by mathematical modeling [49].
In addition to this, the long-term stability of our combi-
nations, and potential cellular affects will need to be
assessed. Direct measurements of expression level could
also be beneficial for refinement of our configurations
and better understanding potential differences resulting
from cassette positions (and how these operate over
time under stable expression). Finally, reformulated
combinations could be investigated using a wider range
of shRNAs reanalyzed to include the following: (1) very
highly active, e.g. > 95%, (2) tested suppressive activity
when expressed in combination, and (3) high strand bias
to reduce competition with the active strand. All these
factors will be important to maximize the impact from
combinations of the smallest effective size.
In summary, we have assembled the most clinically
relevant shRNA combinations to date, and characterized
the intrinsic suppressive activities of both the compo-
nent shRNAs and the combinations as a whole. While
we found all combinations had high combined suppres-
sive activities, there were also large changes in the indi-
vidual activities of the component shRNAs. Though a
useful start, it is not the physical configuration of our
multiple cassette method that is the key finding. Rather,
we have demonstrated that it is possible to assemble
combinations of 4+ highly active, highly conserved
shRNAs that can cover all known variants for entire
subtypes (e.g. clade B). Such combinations could thus be
tailored to geographical sub- t y p ep r e v a l e n c ew i t ht h e
theoretical potential to prevent the emergence of ther-
apy-resistant strains. By extension, our work suggests
that it may also be possible to assemble just a few com-
binations for complete global coverage of all known
HIV-1 variants; something as yet unachievable by any
other means.
Methods
Single target and all-in-one (aio) fluorescent reporter
constructions
The HIV-1 fluorescent protein-target fusion repor-
ter plasmids were constructed using EGFP (from
pd4-d4EGFP-N1, BD Biosciences), AsRed1 (from
pAsRed1-C1, BD Biosciences) and HIV-1 sequences
PCR amplified or synthetically generated from variant
NL4-3 [Genbank:AF324493] (Additional file 1). Each
single target reporter contained GFP fused upstream to
one of the accessory genes (for shRNAs #0, #1, #6, #7,
and #8), a fragment of the core genes (#2, #3, and #9)
or a small shRNA-specific target domain (#4 and #5)
with stop codons placed between the two domains so
that a fused mRNA target was transcribed but only the
GFP domain was translated. The aio reporters were cre-
ated using custom generated target domains (GenScript;
http://www.genscript.com) composed of 9 target
domains matched to our 10 shRNAs, or 7 unmatched
control domains (for the control reporter) which were
transferred via PCR into our EGFP reporter base plas-
mids. The elements of the 406 bp combined target
domain synthesized for the aio sense reporter were
(Xho I-Bgl II {for cloning}-# 9-# 2-# 0 | 1-# 3-# 4-
#5 - #7 - #6 - #8 - Sal I-Bam HI {for cloning}).
Assembly of multiple shRNA expression plasmids
T h ei n f i n i t e l ye x p a n d a b l em u l t i p l ec l o n i n gs i t ew a s
assembled by annealing two complementary synthetic
oligonucleotides, and inserting it into a recipient plas-
mid (a 7 kb carrier plasmid encoding a lentiviral transfer
vector) which was a derivative of pKC(ro
-)MND.MCS
obtained from Cell Genesys, as previously described
[38]. The 10 chosen shRNA targets, and the original
individual shRNA expression plasmids used here as PCR
templates were selected and constructed as previously
described [12,50] (Additional file 1). The multiple
shRNA combinations were assembled in our lentivirus
plasmids by sequentially inserting each PCR amplified
shRNA expression cassette. Because many shRNAs
were present in several combinations, we were able to
minimize construction effort by creating shared sub-
combinations from the most common shRNAs first. As
such, all combinations began with shRNA #3, and had
either #4 or #8 in position 2, #5, #7 or #9 in position 3,
and so on, becoming increasingly diverse for each com-
bination. The PCR primers used to amplify the shRNA
expression cassettes were common to all plasmids; the
forward primer (5’-3’): GC {seat} ACGCGT {Mlu I}
GTT TTC CCA GTC ACG AC {binding site}, and the
reverse primer (5’-3’): GC {seat}G C G A T C G C{ Asi SI}
TTAATTAA {Pac I} CCCGGG {spacer} GGCGCGCC
{Asc I}G C TG C AA T AA AC A AG T TA{ binding site}.
Each PCR consisted of the core 2 primers (20 pmol
each), 1× PCR II buffer (Roche) 2.5 mM MgCl2,1 0m M
dNTPs (each), ~ 100 ng of template, 0.5 μl AmpliTaq-
Gold (Roche), and H2O to a final volume of 50 μl. Each
PCR was cycled at 1×: 94°C for 10 min., 35×: 94°C for
30 sec. | 55°C for 30 sec. | 72°C for 30 sec., and 1 × 72°
C for 10 min. End digestions were conducted directly in
the PCR mix (after cycling) by adding 5 μl of 10× BSA,
1 μle a c ho fMlu Ia n dAsi SI and incubating @ 37°C
for a minimum of 1 hr. All restriction enzymes were
sourced from New England Biolabs (NEB). Digested cas-
settes were separated on 2% TAE agarose gels, gel
extracted (Qiagen Gel Extraction kit) and eluted in
35 μlo fH 2O. Recipient plasmids were prepared by
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NEB 4 buffer, BSA plus H2Ot oaf i n a lv o l u m eo f5 0μl
and incubation at 37°C overnight. This was followed by
heat inactivation (65°C for 20 min.) and de-phosphoryla-
tion by adding 5 μl Antarctic Phosphatase (NEB), 5 μl
buffer and incubating at 37°C for a minimum of 1 hr.
Antarctic Phosphatase was heat inactivated (65°C for 10
min) prior to separation on 1% TAE agarose gels and
gel extraction (performed as already described). Single
donor cassettes were ligated into the linearized recipient
plasmid using 4 μl of vector, 6 μlo fs h R N Ac a s s e t t e ,1 0
μl of Quick DNA ligase buffer and 1 μlo fQ u i c kD N A
ligase (NEB). The ligations were incubated at room tem-
perature for 5 min., and then purified using the QIAgen
PCR Purification kit by mixing with 5 volumes (105 μl)
of Buffer PB, and eluting in 35 μlH 2O. Ligated products
were transformed by electroporation under standard
conditions, and positive colonies were identified by a
direct colony PCR technique using Pfu polymerase. All
plasmids were propagated in GT116 E. coli cells; a cell
line specifically developed for the replication of hairpin
containing plasmids (Invivogen). DNA was extracted
(Hi-speed Maxi-prep Kit, Qiagen), quantitated in tripli-
cate (Nanodrop) and sequence confirmed via automated
sequencing.
Pfu-based PCR screening and gel electrophoresis
As previously described [38], inserted donor fragments
were screened by gel analysis of PCR amplicons made
using primers that flanked the MCS; forward (5’-3’):
AGT TCT GCA CTC GGC CTC TG, and reverse (5’-
3’): CCA TGG TCT GCA GTC GCT AG. These were
positioned 38 bp upstream and 21 bp downstream
(inclusive). The optimized Pfu-based PCR screening
method consisted of the primers (20 pmol each), 1 ×
Pfu Ultra II HS buffer (Stratagene), 3.5 mM MgCl2
(total), 10 mM dNTPs (each), ~ 10 ng of template, 2.5
μl DMSO (5%), 0.5 μlP f uU l t r aI IH S( S t r a t a g e n e ) ,a n d
H2O to a final volume of 50 μl. Each PCR was cycled at
1×: 95°C for 2 min., 35×: 95°C for 20 sec. | 66°C for 20
sec. | 72°C for 0.5 - 4 min. (depending upon template
length), and 1× 72°C for 3 min. Samples were electro-
phoresed on 1% TAE agarose gels plus 0.01% SYBRSafe
stain (Invitrogen) at 200 V (limiting) for ~ 60 min.
using a 150 × 245 mm tray, 3 mm wells with a Bio-Rad
sub-cell model 192 apparatus.
Sequence confirmation
The sequence of each sub- and all final combinations
were verified by automated sequencing, which was tech-
nically challenging due to high amounts of secondary
structure resulting in poor reads, and the lack of unique
binding sites due to repeated sequence shared amongst
all cassettes. It required the use of the external primers
previously described for the PCR screening method
(binding to flanking plasmid regions) and shRNA speci-
fic primers (designed to overlap unique stem regions) to
create contiguous partial sequence reads that could be
assembled into single continuous reads using Codon-
Code Aligner for Mac OS × (CodonCode Corporation;
http://www.codoncode.com).
Fluorescent reporter assay
Each shRNA expression plasmid was co-transfected
with two reporters; the corresponding target-specific
G F Pf u s i o na n dan o n - s p e c i f i cA s R e d - 1f u s i o n .T h e
non-specific reporter was typically an AsRed-1-Vpr
fusion, since we selected no Vpr shRNA targets. Low
passage no. HEK293a cells (sourced from the American
Type Culture Collection) [ATCC:CRL-1573]w e r e
seeded at a density of 5 × 10
5 cells per well (6 well
plates; 2 ml of medium). Cells were transfected 1 day
later using 1 μg of total DNA (400 ng of shRNA
expression plasmid, 300 ng of target plasmid and 300
ng of control plasmid) with 4 μl of Lipofectamine 2000
(Invitrogen) in OptiMEM (Invitrogen) to a total
volume of 100 μl/well. For titration experiments up to
400 ng of shRNA expression plasmid was supplemen-
ted with the appropriate amount of the corresponding
empty expression control plasmid to a total amount of
400 ng as indicated. Cells were analyzed by flow cyto-
metry ~ 48 hours later (FACsCalibur and CellQuest
P r of o rM a cO SX ,B DB i o s c i e n c e s ) .T a r g e t - s p e c i f i c
suppression was measured as a decrease in green fluor-
escence (FL1 channel) and non-specific effects were
measured as a change in red fluorescence (FL2 chan-
nel). The Fluorescence Index (FI) of cells in each chan-
nel was calculated by multiplying the geo mean of
fluorescence by the percentage of cells that were fluor-
escent (only those cells gated above background).
The FI of FL1 (green, target-specific activity) was
normalized to remove non-specific effects (FI of FL1
normalized to the FI of FL2) and was expressed as a
percentage of the FI of cells transfected only with the
control plasmid that expressed no shRNA. Each experi-
ment included a mock transfection (i.e. no DNA) and
an off-target shRNA control (to verify that on-target
shRNA suppression was sequence-specific), both of
which behaved as expected and both of which were
o m i t t e df r o mt h eg r a p h sf o rc l a r i t y .
Additional material
Additional file 1: Contains additional data for the control
sequences, detailed conservation profiles for the 10 selected
shRNAs, detailed construction methods for the single shRNA
expression plasmids and sequences for the reporter (mapped with
the chosen shRNAs) and control sequences.
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